IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
Apple Tree Life Sciences, Inc., *et al.*,[1]	)	Case No. 25-12177 (LSS)
Debtors.	)	Jointly Administered
	)	**Obj. Deadline: November 2, 2026 at 4:00 PM (ET)**
	)	**Hearing Date: November 10, 2026 at 10:00 AM (ET)**

APPLICATION OF DEBTOR ATP LIFE SCIENCE VENTURES, L.P. FOR AN ORDER AUTHORIZING AND APPROVING THE EMPLOYMENT AND RETENTION OF ORRICK, HERRINGTON & SUTCLIFFE LLP AS CO-COUNSEL, EFFECTIVE AS OF SEPTEMBER 28, 2026

Debtor ATP Life Science Ventures, L.P. (the "Fund Debtor") hereby files this application (the "Application"), pursuant to section 327(a) of title 11 of the United States Code (the "Bankruptcy Code"), rule 2014 of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules"), and rule 2014-1 of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the District of Delaware (as amended, the "Local Rules"), for the entry of an order, substantially in the form attached hereto as Exhibit A, authorizing and approving the employment and retention of Orrick, Herrington & Sutcliffe LLP ("Orrick") as co-counsel to the Fund Debtor. In support of this Application, the Fund Debtor submits the Declaration of David Litterine-Kaufman, a copy of which is attached hereto as Exhibit B (the "Litterine-Kaufman

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

2512177261019000000000009

Declaration"), and the Declaration of Barry Lynch on Behalf of the Fund Debtor, a copy of which is attached hereto as Exhibit C (the "Lynch Declaration"), and respectfully states as follows:

BACKGROUND

1. On December 9, 2025, December 15, 2025 and January 1, 2026 (collectively, the "Petition Dates"), the above-captioned debtors (collectively, the "Debtors") filed voluntary petitions for relief under chapter 11 of the Bankruptcy Code with this Court (the "Chapter 11 Cases").

2. As of the date hereof, the Debtors continue as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code, and no trustee or examiner has been requested or appointed in these cases.

3. The Debtors comprise a biotechnology venture capital investment fund and certain portfolio companies operating and investing in the United States, in which the Fund Debtor owns equity interests. The Fund Debtor, a Cayman Islands exempted limited partnership formed in 2012, is the Debtors' primary investment vehicle. Before July 10, 2026, and pursuant to the Fund Debtor's limited partnership agreement, ATP III GP Ltd, as general partner ("GP"), managed the Fund Debtor's investments and operations, subject to budget-approval rights.

4. On July 10, 2026, the Grand Court of the Cayman Islands (the "Cayman Court") entered an order declaring that the Fund Debtor lost its substratum and consequently appointed Alexander Lawson and Barry Lynch as joint officeholders (the "Officeholders") to act on behalf of the Fund Debtor in place of the GP (the "Cayman Order").

5. On July 30, 2026, the Court entered the *Order Recognizing Officeholders* [Docket No. 1000] recognizing the Officeholders' appointment by the Cayman Court "to act in the stead

of the [GP] . . . and to carry out the management, policies and control of the affairs and the conduct of the business of the [Fund Debtor]."

6. On September 22, 2026, the Court entered the *Order (I) Authorizing the Fund Debtor to Retain and Employ DLA Piper LLP (US) as Counsel Effective as of July 10, 2026 and (II) Granting Related Relief* [Docket No. 1155] approving the Fund Debtor's retention of DLA Piper LLP (US) ("DLA") as counsel in the Chapter 11 Cases.

7. On September 28, 2026, the Fund Debtor selected Orrick to serve as co-counsel with DLA.

JURISDICTION AND VENUE

8. The Court has jurisdiction over this Application pursuant to 28 U.S.C. §§ 157 and 1334. Venue is proper in this District pursuant to 28 U.S.C. §§ 1408 and 1409. This is a core proceeding pursuant to 28 U.S.C. § 157(b)(2). The statutory predicates for the relief requested herein are section 327(a) of the Bankruptcy Code, Bankruptcy Rule 2014, and Local Rule 2014-1.

9. Pursuant to Local Rule 9013-1(f), the Fund Debtor consents to the entry of a final judgment or order with respect to the Application, even if it is determined that the Court, absent consent of the parties, cannot enter final orders or judgments consistent with Article III of the United States Constitution.

RELIEF REQUESTED

10. By this Application, pursuant to section 327(a) of the Bankruptcy Code, Bankruptcy Rule 2014, and Local Rule 2014-1, the Fund Debtor requests entry of the proposed order attached hereto as Exhibit A, authorizing and approving the employment and retention of Orrick in connection with these Chapter 11 Cases.

ORRICK'S QUALIFICATIONS AND SERVICES TO BE RENDERED

11. The Fund Debtor wishes to retain Orrick as bankruptcy co-counsel to represent it in the Chapter 11 Cases. The Fund Debtor requires co-counsel with experience in this district and in complex cross-border business reorganizations, insolvency matters, and commercial law issues, including complex, multi-jurisdictional litigation involving domestic and foreign entities. Among other matters, Orrick has represented creditors or other major stakeholders in cases in this district, including *In re Sangamo Therapeutics*, Inc., No. 26-10989 (Bankr. D. Del. filed June 23, 2026); *In re Freedom Forever LLC*, No. 26-10522 (Bankr. D. Del. filed April 15, 2026); *In re FLOAT Alaska LLC, et al.*, No. 26-10075 (Bankr. D. Del. filed January 26, 2026); *In re AGDP Holding Inc., et al*., No. 25-11446 (Bankr. D. Del. filed August 4, 2025); *PCT Litigation Trust v. Plutus Lending LLC*, No. 25-50960 (Bankr. D. Del. filed May 27, 2025); *In re DeCurtis Holdings LLC*, No. 23-10548 (Bankr. D. Del. filed April 30, 2023); *In re Acerus Pharmaceuticals Corp., et al.*, No. 23-10111 (Bankr. D. Del. filed January 29, 2023) ("Acerus"); *In re PhaseBio Pharmaceuticals, Inc*., No. 22-10995 (Bankr. D. Del. filed October 23, 2022); and *In re Xebec Holding USA Inc., et al*., No. 22-10934 (Bankr. D. Del. filed September 30, 2022) ("Xebec"); cases involving offshore and other foreign entities, including *Acerus* (Chapter 15 case ancillary to Canadian insolvency proceeding); *Xebec* (Chapter 15 case ancillary to Canadian insolvency proceeding); *In re Lion Ribbon Texas Corp., et al*., No. 25-90164 (Bankr. S.D. Tex. filed July 3, 2025) (Chapter 11 case involving sale of U.S. debtor by English parent); *In re Asbestos Corp. Ltd*., No. 25-10934 (Bankr. S.D.N.Y. filed May 6, 2025) (Chapter 15 ancillary to Canadian insolvency proceeding); and *In re Ocean Rig Udw Inc*., No. 17-10736 (Bankr. S.D.N.Y. filed March 27, 2017) (Chapter 15 case ancillary to Cayman Islands insolvency proceeding); and other complex bankruptcy cases across multiple jurisdictions, including *Byman v. Katzman, et al*., No. 25-03778

(Bankr. S.D. Tex. filed October 10, 2025); *In re Linqto Texas, LLC, et al.*, No. 25-90186 (Bankr. S.D. Tex. filed July 7, 2025); and *In re Strudel Holdings LLC and AVR AH LLC*, No. 23-90757 (Bankr. S.D. Tex. filed July 27, 2023).

12. Orrick has agreed to act on behalf of, and to render such services to, the Fund Debtor. In performance of such duties, Orrick shall report to the Fund Debtor.

13. The Fund Debtor believes that it is necessary and in the best interest of the Fund Debtor and its estate to obtain these services from Orrick, that the services provided by Orrick will not duplicate the services that other professionals will be providing to the Debtors in these Chapter 11 Cases, and that Orrick is well qualified to handle the legal work required in these Chapter 11 Cases.

14. The Fund Debtor has informed Orrick, and Orrick understands, that the Fund Debtor has retained other professionals in these Chapter 11 Cases, including DLA as general section 327(a) counsel. The Fund Debtor wishes to retain Orrick to augment and enhance the services being provided by the Fund Debtor's other professionals and has directed Orrick and the other professionals that they are to work closely to ensure that there is no unnecessary duplication of services. To that end, Orrick will coordinate workstreams with the Fund Debtor and such other professionals to maximize efficiency. The Fund Debtor submits that this approach will best serve the interests of the Fund Debtor given the level of activity and complexity of the Debtors' cases.

DISCLOSURES

15. As more fully set forth in the Litterine-Kaufman Declaration attached hereto as Exhibit B, Orrick reviewed the list of interested persons and entities included on Schedule 1 to the Litterine-Kaufman Declaration (the "Potential Parties in Interest") and searched Orrick's client database for the last three years and Orrick's vendor and insurance carrier databases to determine

whether Orrick had, within such period of time, any connections to the Potential Parties in Interest. The Potential Parties in Interest consist of each of the names set forth in the list of parties in interest provided to Orrick by the Debtors (the "Debtors' Interested Party List"),[2] and, to the extent identified by Orrick, the names of additional parties identified in other filings in these Chapter 11 Cases. The results of Orrick's conflicts search are set forth on Schedule 2 to the Litterine-Kaufman Declaration. To the best of the Fund Debtor's knowledge, the Fund Debtor believes that Orrick is "disinterested," as that term is defined in section 101(14) of the Bankruptcy Code, and does not hold or represent an interest adverse to the Fund Debtor's estate with respect to the matters for which Orrick is to be employed, as required by section 328(c) of the Bankruptcy Code.

16. The Fund Debtor is aware that Orrick is a large firm with a national practice and currently represents or has represented certain of the Potential Parties in Interest in matters unrelated to these Chapter 11 Cases, as further identified in the Litterine-Kaufman Declaration and listed on Schedule 2 thereto. While employed by the Fund Debtor, Orrick will not represent any such interested parties in any matter related to these Chapter 11 Cases. The Fund Debtor hereby waives any conflict of interest that exists or may exist due to Orrick's representation of such Potential Parties in Interest in matters unrelated to these Chapter 11 Cases.

17. The Fund Debtor does not believe that Orrick's representation of any of the Potential Parties in Interest or their affiliate(s) in unrelated matters will impair Orrick's ability to represent the Fund Debtor as co-counsel in connection with these Chapter 11 Cases. The Fund Debtor has been informed that Orrick will conduct ongoing review of its files to ensure that no disqualifying circumstances arise. To the extent that Orrick discovers any connection with any of

[2] Orrick did not perform any independent diligence with respect to the accuracy of the Debtors' Interested Party List.

the Potential Parties in Interest or enters into any new relationship with any of the Potential Parties in Interest, Orrick will promptly supplement its disclosures to the Court.

COMPENSATION OF ORRICK

18. Orrick has agreed to make appropriate applications to this Court for compensation and reimbursement of expenses in compliance with the Bankruptcy Code, the Bankruptcy Rules, the Local Rules and any Order entered by this Court in these Chapter 11 Cases modifying the timing and/or procedures applicable to the payment of interim compensation and reimbursement of expenses.

19. The principal attorneys and paraprofessionals that Orrick anticipates will be primarily responsible for advising and assisting the Fund Debtor and their current hourly rates are as follows:

Evan C. Hollander (Partner)	$2,285.00
David Litterine-Kaufman (Partner)	$1,755.00
Nicholas Poli (Partner)	$1,715.00
Nicholas Sabatino (Senior Associate)	$1,505.00
Alexandra Zablocki (Managing Associate)	$1,455.00
Lenni Elias (Associate)	$885.00
Paraprofessionals	$395.00 - $830.00

20. Orrick's hourly rates are subject to periodic increases in the normal course of Orrick's business. In the event of any such increase, Orrick will provide the U.S. Trustee, the Fund Debtor, the other Debtors and any committee appointed by this Court with ten (10) days' written notice of any such increase and file a notice of such increase with the Court; *provided*, *however*, that in the event Orrick attorneys responsible for this matter do not have sufficient advance notice of such rate increases, Orrick shall provide notice to the Fund Debtor, the U.S. Trustee, the other Debtors and any committee appointed by this Court within a reasonable time after the information regarding rate increases becomes available to the Orrick attorneys responsible for this matter.

21. From time to time, other attorneys at Orrick may provide services to the Fund Debtor, including certain "project" attorneys on our staff in our Wheeling, WV offices to manage discovery-related workstreams and "contract" attorneys to assist with such workstreams (subject to the terms of the Court's order approving Orrick's retention concerning contract attorneys).

22. Orrick will charge the Fund Debtor for all other out-of-pocket expenses and disbursements generally charged to its clients in all areas of practice and in accordance with the Bankruptcy Rules, the Local Rules, the U.S. Trustee Guidelines, and any applicable orders of this Court. The customary expenses charged include, among other things, photocopying charges, filing costs, postage, witness fees, travel expenses, expenses for business meals, computerized research, messengers, couriers, other fees related to trials and hearings (including transcripts), as well as non-ordinary expenses.

STATEMENT REGARDING UNITED STATES TRUSTEE GUIDELINES

23. The Fund Debtor understands that Orrick intends to apply for compensation for professional services rendered and reimbursement of expenses incurred in connection with the Debtors' Chapter 11 Cases in compliance with sections 330 and 331 of the Bankruptcy Code and applicable provisions of the Bankruptcy Rules, Local Rules, and any other applicable procedures and orders of the Court. The Fund Debtor and Orrick will make a reasonable effort to comply with the U.S. Trustee's reasonable requests for information and additional disclosures as set forth in the *Guidelines for Reviewing Applications for Compensation and Reimbursement of Expenses Filed Under 11 U.S.C. § 330 by Attorneys in Larger Chapter 11 Cases Effective as of November 1, 2013* (the "U.S. Trustee Guidelines"), the *Order (I) Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals and (II) Granting Related Relief* [Docket No. 181] (the "Interim Compensation Order"), and the *Order Appointing Fee Examiner*

and Establishing Related Procedures Concerning Compensation and Reimbursement of Expenses and Professionals and Members of Official Committees and Consideration of Fee Applications [Docket No. 527], both in connection with this Application and the interim and final fee applications to be filed by Orrick.

24. As set forth in the Litterine-Kaufman Declaration, the following is provided in response to the request for additional information set forth in Paragraph D.1 of the U.S. Trustee Guidelines:

(a) No professional included in this engagement varies their rate based on the geographic location of the bankruptcy case.

(b) Orrick has not represented the Fund Debtor in the 12 months prepetition and, consequently, there are no billing rates and material financial terms for the prepetition engagement, including any adjustments during the 12 months prepetition to disclose, and Orrick's billing rates and material financial terms have not changed postpetition.

(c) Orrick will provide such information as the Fund Debtor requests or requires for it to prepare and submit budget and staffing plans required under the U.S. Trustee Guidelines.

25. The Fund Debtor requests approval of the employment of Orrick as co-counsel, effective as of September 28, 2026. Such relief is warranted by the circumstances presented by these Chapter 11 Cases.

NO PRIOR REQUEST

26. No previous request for the relief sought herein has been made to this or any other court.

NOTICE

27. Notice of this Application is being given to: (i) the Debtors; (ii) the U.S. Trustee; (iii) the Official Committee of Unsecured Creditors appointed in this case; and (iv) any party that has requested notice pursuant to Bankruptcy Rule 2002 in this case. Due to the nature of the relief requested herein, the Fund Debtor respectfully submits that no further notice of this Application is necessary.

[*Remainder of page intentionally left blank*]

WHEREFORE, the Fund Debtor respectfully requests entry of an order, in a form substantially similar to that attached hereto as Exhibit A, pursuant to section 327(a) of the Bankruptcy Code, authorizing and approving the retention and employment of Orrick as co-counsel to the Fund Debtor in these Chapter 11 Cases, effective as of September 28, 2026, and granting such other and further relief as may be just and proper.

Dated: October 19, 2026
George Town, Cayman Islands

ATP LIFE SCIENCE VENTURES, L.P.

/s/ Barry Lynch
Barry Lynch, solely in his capacity as an Officeholder of the Fund Debtor

EXHIBIT A

Proposed Order

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
Apple Tree Life Sciences, Inc., *et al.*,[1]	)	Case No. 25-12177 (LSS)
Debtors.	)	Jointly Administered
	)	**Related to Docket No. ____**

ORDER PURSUANT TO 11 U.S.C. § 327(a) AUTHORIZING AND APPROVING THE EMPLOYMENT AND RETENTION OF ORRICK, HERRINGTON & SUTCLIFFE LLP AS CO-COUNSEL TO DEBTOR ATP LIFE SCIENCE VENTURES, L.P., EFFECTIVE AS OF SEPTEMBER 28, 2026

Upon consideration of the application (the "Application")[2] of Debtor ATP Life Science Ventures, L.P. (the "Fund Debtor") in the Chapter 11 Cases of the above-captioned debtors and debtors-in-possession (the "Debtors") for entry of an order authorizing and approving the employment and retention of Orrick, Herrington & Sutcliffe LLP ("Orrick") as co-counsel to the Fund Debtor, effective as of September 28, 2026, and upon the Litterine-Kaufman Declaration and Lynch Declaration, as annexed thereto, and it appearing that proper notice of the Application has been given and that no further notice or hearing is required, and the Court being satisfied based on the representations made in the Application and declarations that (i) Orrick represents no interest

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

[2] Capitalized terms used but not otherwise defined herein have the meanings given to them in the Application.

adverse to the Debtors' estates, creditors, or equity holders, (ii) Orrick is a "disinterested person" as that term is defined in section 101(14) of the Bankruptcy Code, and (iii) the employment of Orrick is necessary and would be in the best interest of the Fund Debtor and its estate, and after due deliberation, and sufficient cause appearing therefor, it is hereby

ORDERED that the Application is granted as set forth herein; and it is further

ORDERED that in accordance with section 327(a) of title 11 of the United States Code (the "Bankruptcy Code"), the Fund Debtor is hereby authorized and empowered to retain Orrick as co-counsel, effective as of September 28, 2026, to represent the Fund Debtor in its case under chapter 11 of the Bankruptcy Code in accordance with the terms set forth in the Application; and it is further

ORDERED that Orrick shall be compensated in accordance with the procedures set forth in sections 330 and 331 of the Bankruptcy Code, the Bankruptcy Rules, the Local Rules, and any applicable procedures and orders of the Court; and it is further

ORDERED that Orrick shall make a reasonable effort to comply with the U.S. Trustee's requests for information and additional disclosures as set forth in the *Guidelines for Reviewing Applications for Compensation and Reimbursement of Expenses Filed under 11 U.S.C. § 330 by Attorneys in Larger Chapter 11 Cases Effective as of November 1, 2013*, both in connection with the Application and the interim and final fee applications to be filed by Orrick in these Chapter 11 Cases; and it is further

ORDERED that Orrick will review its files periodically during the pendency of the Chapter 11 Cases to ensure that no conflicts or other disqualifying circumstances exist or arise and, if any new relevant facts or relationships are discovered or arise, Orrick will use reasonable

efforts to identify such further developments and will promptly file a supplemental declaration, as required by Bankruptcy Rule 2014(a); and it is further

ORDERED that Orrick shall use its reasonable efforts to avoid any duplication of services provided by any of the Fund Debtor's other retained professionals in these Chapter 11 Cases; and it is further

ORDERED that Orrick will not charge a markup to the Fund Debtor with respect to fees billed by contract attorneys who are hired by Orrick to provide services to the Fund Debtor and shall ensure that any such contract attorneys are subject to conflict checks and disclosures in accordance with the requirements of the Bankruptcy Code and the Bankruptcy Rules. For the avoidance of doubt, Orrick shall not share fees with existing or future contract attorneys who advise the Fund Debtor or enter into fee-sharing arrangements with such contract attorneys; and it is further

ORDERED that Orrick will provide ten (10) days' advance written notice of any rate increases to the Fund Debtor, the U.S. Trustee, the other Debtors, and any committee appointed by this Court before any increases in the rates set forth in the Application or the Litterine-Kaufman Declaration are implemented and shall file such notice with the Court; *provided, however*, that in the event Orrick attorneys responsible for this matter do not have sufficient advance notice of such rate increases, Orrick shall provide notice to the Fund Debtor, the U.S. Trustee, the other Debtors and any committee appointed by this Court within a reasonable time after the information regarding rate increases becomes available to the Orrick attorneys responsible for this matter. The Fund Debtor, the other Debtors, the U.S. Trustee, any committee appointed by this Court and all parties in interest retain all rights to object to any rate increase on all grounds including, but not

limited to, the reasonableness standard provided for in section 330 of the Bankruptcy Code, and the Court retains the right to review any rate increase pursuant to section 330 of the Bankruptcy Code; and it is further

ORDERED that during the course of the Chapter 11 Cases, this Court has and shall retain exclusive jurisdiction to hear and determine all matters arising from the implementation of this Order.

EXHIBIT B

Declaration of David Litterine-Kaufman

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
Apple Tree Life Sciences, Inc., *et al.*,[1]	)	Case No. 25-12177 (LSS)
Debtors.	)	Jointly Administered
	)	**Related to Docket No. ___**

DECLARATION OF DAVID LITTERINE-KAUFMAN IN SUPPORT OF APPLICATION OF ATP LIFE SCIENCE VENTURES, L.P. FOR AN ORDER AUTHORIZING AND APPROVING THE EMPLOYMENT AND RETENTION OF ORRICK, HERRINGTON & SUTCLIFFE LLP AS CO-COUNSEL, EFFECTIVE AS OF SEPTEMBER 28, 2026

David Litterine-Kaufman, being duly sworn, states the following under penalty of perjury:

1. I am an attorney at law admitted to practice in the State of New York. I am a partner at the firm of Orrick, Herrington & Sutcliffe LLP ("Orrick"), which maintains offices at 51 West 52nd Street, New York, New York, as well as in other cities across the world. I am familiar with the matters set forth herein and I am authorized to make this declaration on behalf of Orrick.

2. Orrick has agreed to be retained and employed, subject to Court approval, to provide legal services and assistance to Debtor ATP Life Science Ventures, L.P. (the "Fund Debtor") in the Chapter 11 Cases of the above-captioned debtors and debtors-in-possession (the "Debtors"), and I provide this declaration pursuant to section 327 of the Bankruptcy Code,

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

section 1746 of title 28, United States Code, Bankruptcy Rule 2014(a), and Local Rule 2014-1 in support of the Application (the "Application")[2] of the Fund Debtor seeking approval to employ Orrick, effective as of September 28, 2026, as co-counsel to the Fund Debtor pursuant to section 327(a) of the Bankruptcy Code.

3. Orrick has agreed to represent the Fund Debtor and provide general legal services as needed throughout the course of these Chapter 11 Cases.

4. In performance of such duties, Orrick shall report to the Fund Debtor.

5. The Fund Debtor believes that it is necessary and in the best interest of the Fund Debtor and its estate to obtain these services from Orrick, that the services provided by Orrick will augment and enhance and not duplicate the services that other professionals will be providing to the Debtors in these Chapter 11 Cases, and that Orrick is well qualified to handle the legal work required in these Chapter 11 Cases.

6. Orrick intends to work closely with the representatives of the Fund Debtor and the other professionals retained by the Fund Debtor to ensure that there is no unnecessary duplication of services performed or charged to the Fund Debtor's estate.

7. In connection with its proposed employment by the Fund Debtor in these Chapter 11 Cases, an attorney working under my supervision reviewed the list of interested persons and entities included on Schedule 1 attached hereto (the "Potential Parties in Interest") and searched Orrick's client database for the last three years and Orrick's vendor and insurance carrier databases to determine whether Orrick had, within such period of time, any connections to

[2] Capitalized terms used but not otherwise defined herein have the meanings given to them in the Application.

the Potential Parties in Interest. The Potential Parties in Interest consist of each of the names set forth in the list of parties in interest provided to Orrick by the Debtors (the "Debtors' Interested Party List")[3] and, to the extent identified by Orrick, the names of entities and persons identified in other filings made in these Chapter 11 Cases. Orrick's conflict search resulted in the disclosures set forth on Schedule 2 attached hereto.

8. Based upon information currently available to me, Orrick has no connection with the Fund Debtor, its creditors, or any other party in interest, their attorneys and accountants, the U.S. Trustee or any person employed in the office of the U.S. Trustee, or any judge in the Bankruptcy Court or District Court for the District of Delaware or any person in the offices of the same, except as set forth below and on Schedule 2 attached hereto.

9. The Debtors have numerous relationships and creditors. Consequently, although every reasonable effort has been made to discover and eliminate the possibility of any connection or conflict, including the efforts outlined above, Orrick is unable to state with certainty whether any more of its clients or such clients' affiliated entities hold claims or otherwise are parties in interest in these Chapter 11 Cases. If Orrick discovers any information that is contrary to or pertinent to the statements made herein, Orrick will promptly disclose such information to the Court on notice to the creditors and the U.S. Trustee.

10. To the best of my knowledge Orrick is a "disinterested person" as that term is defined in section 101(14) of the Bankruptcy Code and as used in section 328(c) of the Bankruptcy

[3] Orrick did not perform any independent diligence with respect to the accuracy of the Debtors' Interested Party List.

Code, and does not have an interest materially adverse to the interests of the Debtors' estates or any class of creditors or equity holders of the Debtors.

11. The Fund Debtor is aware that Orrick is a large firm with a national practice and currently represents or has represented certain of the Potential Parties in Interest in matters unrelated to these Chapter 11 Cases, as further identified herein and listed on Schedule 2 hereto. While employed by the Fund Debtor, Orrick will not represent any such interested parties in any matter related to these Chapter 11 Cases.

12. Orrick will promptly file with the Court a supplemental declaration if and when any further connections between it and such Potential Parties in Interest are discovered.

13. To the best of my knowledge, and except as set forth herein, neither Orrick nor any attorney at the firm: (a) holds or represents an interest adverse to the Debtors' estates; (b) is or was a creditor, an equity security holder or an insider of the Debtors; (c) is or was, within two years before the Petition Date, a director, officer, or employee of the Debtors; or (d) has an interest materially adverse to the interests of the estate or of any class of creditors or equity security holders, by reason of any direct or indirect relationship to, connection with, or interest in the Debtors, or for any other reason. Orrick avers that none of its connections to the Potential Parties in Interest disclosed herein are disqualifying.

14. Due to the size and diversity of its practice, Orrick may have represented or otherwise dealt with, and may now be representing or otherwise dealing with, various persons (and their attorneys and accountants) who are or may consider themselves creditors, equity security holders or parties in interest in this case but who are not presently identified as Potential Parties in

Interest. However, such representation or involvement, if any, does not relate to the Debtors or their estates.

15. In addition to the foregoing, Orrick's partners and employees may have business associations with, professional, social, or familial relationships with, or interests aligned with or adverse to, creditors or parties in interest, or their attorneys, accountants, or advisors. As part of its practice, Orrick appears in cases, proceedings, and transactions throughout the world involving many different parties, and works together with many different parties, which may include creditors or parties in interest, or attorneys, accountants, or other professional firms or advisors who may represent creditors or parties in interest in this case. To the best of my knowledge, none of these associations, relationships, or interests have any connection with the Fund Debtor, the other Debtors, or these Chapter 11 Cases.

16. In addition, to the best of my knowledge, information, and belief and in accordance with Bankruptcy Rule 5002, neither I, nor any attorney at Orrick is a relative of the United States Bankruptcy Judge for the District of Delaware assigned to this case or of the U.S. Trustee, and Orrick is not a relative of and does not have a connection with any United States Bankruptcy Judge for the District of Delaware or the U.S. Trustee that would render its retention in this case improper.

17. Orrick will conduct an ongoing review of its files to ensure that no disqualifying circumstances arise. To the extent that Orrick discovers any connection with any of the Potential Parties in Interest or enters into any new relationship with any of the Potential Parties in Interest, Orrick will promptly supplement its disclosures to the Court.

18. Orrick has not received a retainer or compensation in connection with its proposed representation of the Fund Debtor in these Chapter 11 Cases.

19. No agreement exists, nor will any be made, to share any compensation received by Orrick for its services with any other person or firm other than to share this compensation among its partners, associates, and employees.

20. The principal attorneys and paraprofessionals that Orrick anticipates will be primarily responsible for advising and assisting the Fund Debtor and their current hourly rates are as follows:

Evan C. Hollander (Partner)	$2,285.00
David Litterine-Kaufman (Partner)	$1,755.00
Nicholas Poli (Partner)	$1,715.00
Nicholas Sabatino (Senior Associate)	$1,505.00
Alexandra Zablocki (Managing Associate)	$1,455.00
Lenni Elias (Associate)	$885.00
Paraprofessionals	$395.00 - $830.00

21. Orrick's hourly rates are subject to periodic increases in the normal course of Orrick's business. In the event of any such increase, Orrick will provide the U.S. Trustee, the Fund Debtor, the other Debtors and any committee appointed by this Court with ten (10) days' written notice of any such increase and file a notice of such increase with the Court; *provided, however*, that in the event Orrick attorneys responsible for this matter do not have sufficient advance notice of such rate increases, Orrick shall provide notice to the Fund Debtor, the U.S. Trustee, the other Debtors and any committee appointed by this Court within a reasonable time after the information regarding rate increases becomes available to the Orrick attorneys responsible for this matter.

22. From time to time, other attorneys at Orrick may provide services to the Fund Debtor, including certain "project" attorneys on our staff in our Wheeling, WV offices to manage

discovery-related workstreams and "contract" attorneys to assist with such workstreams (subject to the terms of the Court's order approving Orrick's retention concerning contract attorneys).

23. Orrick will charge the Fund Debtor for all other out-of-pocket expenses and disbursements generally charged to its clients in all areas of practice and in accordance with the Bankruptcy Rules, the Local Rules, the U.S. Trustee Guidelines, and any applicable orders of this Court. The customary expenses charged include, among other things, photocopying charges, filing costs, postage, witness fees, travel expenses, expenses for business meals, computerized research, messengers, couriers, other fees related to trials and hearings (including transcripts), as well as non-ordinary expenses.

24. Orrick is willing to be employed by the Fund Debtor as its co-counsel under the terms as set forth in the Application and will make appropriate application to this Court for compensation and reimbursement of out-of-pocket expenses, all in accordance with the provisions of the Bankruptcy Code, the Bankruptcy Rules, the Local Rules and any orders of the Court entered in these Chapter 11 Cases. The Fund Debtor and Orrick will make a reasonable effort to comply with the U.S. Trustee's requests for information and additional disclosures as set forth in the *Guidelines for Reviewing Applications for Compensation and Reimbursement of Expenses Filed under 11 U.S.C. § 330 by Attorneys in Larger Chapter 11 Cases Effective as of November 1, 2013* (the "U.S. Trustee Guidelines") and the *Order (I) Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals and (II) Granting Related Relief* [Docket No. 181] (the "Interim Compensation Order"), both in connection with the Application and the interim and final fee applications to be filed by Orrick in these Chapter 11 Cases.

25. The following is provided in response to the request for additional information set forth in Paragraph D.1 of the U.S. Trustee Guidelines:

(a) No professional included in this engagement varies their rate based on the geographic location of the bankruptcy case.

(b) Orrick has not represented the Fund Debtor in the 12 months prepetition and, consequently, there are no billing rates and material financial terms for the prepetition engagement, including any adjustments during the 12 months prepetition to disclose, and Orrick's billing rates and material financial terms have not changed postpetition.

(c) Orrick will provide such information as the Fund Debtor requests or requires for it to prepare and submit budget and staffing plans required under the U.S. Trustee Guidelines.

[*Remainder of page intentionally left blank*]

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct.

Dated: October 19, 2026

/s/ David Litterine-Kaufman
David Litterine-Kaufman, Partner
Orrick, Herrington & Sutcliffe LLP

SCHEDULE 1

Potential Parties in Interest

Debtors
Apple Tree Life Sciences, Inc.
ATP Life Science Ventures, L.P.
ATP III GP, Ltd.
Apertor Pharmaceuticals, Inc.
Evercrisp Biosciences, Inc.
Initial Therapeutics, Inc.
Marlinspike Therapeutics, Inc.
Nereid Therapeutics
Nine Square Therapeutics, Inc.
Red Queen Therapeutics, Inc.

Banks
Banc of California
Citizens Bank
Eastern Bank
JP Morgan Chase Bank, N.A.
Western Alliance Bank

Vendors
AAAS
BioCentury, Inc.
Boston Globe Life Science Media
Canon
Digital Science & Research Solutions, Inc.
DirectUS
Integration Appliance, Inc.
Prendio LLC
Private Plane Expenses

Consultants
Andrew Bayliffe
Hughes and Hughes Bookkeeping
Newfront Consulting
Ollie Yuav

Contract Counterparties
1Password
American Copy Machines
BCL Search
Citeline
Directus Cloud
EndPointsNews
Evaluate Ltd.

Guidepoint Global, LLC
Insperity
Intapp
Massachusetts Medical Society
New England Journal of Medicine
Nextiva
Palmier Services Ltd.
Science AAAS
Sentient Jet
Springer Nature
Rockefeller University Press Journal of Experimental Medicine
The New York Times

Lessors
Contemporary Information Company
RXR HB Owner, LLC
230 Park Avenue Holdco, LLC

Utilities
8x8
Spectrum
Verizon

Insurance Providers
Coalition Insurance Solutions, Inc.
Continental Casualty Company
Federal Insurance Company
Houston Casualty Company
National Union Fire Insurance Company of Pittsburgh, Pa
Travelers Excess and Surplus Lines Company
Westfield Insurance Company

Bankruptcy Judges, Court Staff, and Clerk of Court for the District of Delaware
Chief Judge Karen B. Owens
Judge John. T. Dorsey
Judge Craig T. Goldblatt
Judge Thomas M. Horan
Judge Brenden L. Shannon
Judge Laurie Selber Silverstein
Judge Kate J. Stickles
Judge Mary F. Walrath
Al Lugano
Amanda Hrycak
Cacia Batts

Claire Brady
Danielle Gadson
Demitra Yeager
Jill Walker
Laura Haney
Laurie Capp
Lora Johnson
Marquietta Lopez
Nickita Barksdale
Nikki Washington
Paula Subda
Rachel Bello
Stephen L. Grant
Xavier Hunt

Staff of the Office of the United States Trustee, Region 3
Andrew R. Vara
Benjemin Hackman
Christine Green
Denis Cooke
Diane Giordano
Dion Wynn
Edith A. Serrano
Elizabeth Thomas
Fang Bu
Hannah M. McCollum
Holly Dice
James R. O'Malley
Jane Leamy
Jonathen Lipshie
Jonathen Nyaku
Joesph Cudia
Joseph McMahon
Juliet Sarkessian
Lauren Attix
Linda Casey
Linda Richenderfer
Micheal Panacio
Nyanquioi Jnoes
Ramona Harris
Richard Schepacarter
Rosa Sierra-Fox
Shakima L. Dortch
Timothy J. Fox, Jr.

Committee Professionals
Cole Schotz P.C.
Dundon Advisers LLC

DIP Lender Parties
Oak Tree Capital Management, Inc.
Alter Domus (US) LLC
Cleary Gottlieb Steen & Hamilton LLP
Holland & Knight

Cayman Appointed Officeholders
Alexander Lawson
Barry Lynch
DLA Piper LLP (US)
Alvarez & Marsal Holdings LLC

Debtor Board Members
Bob Hugin
Edmund Graziani
Joesph Yanchik
Laura Forese
Loren Walensky
Margaret Bigelow
Mark Mitchnick
Matthew Jacobson
Meenu Chhabra Karson
Neena Kadaba
Paul Eisenberg
Seth Harrison
Spiros Liras
Tanja Kortemme

Debtor Officers
Lawrence Lum
John Reilly

Non-Debtor Portfolio Company Directors and Officers
Andrew Geall
Ankeet Jethwa
Anna Batarina
Antoine Papiernik
Aron Knickernocker
Brian Shoichet
Christopher Rader

David Lewis
Dennis Langer
Doug Godshall
Edward Yoon
Himani Bhalla
Jerry Karabelas
Jim Vaselli
Kathy Fernando
Leo Redmund
Mace Rothbenberg
Micheal Derkacz
Micheal Ehlers
Micheal Wasserman
Mikael Dolsten
Nathaniel Wang
Neal P. Goldman
Parinaz Aliahmad
Patrick Kennedy
Paul Da Silva Jardine
Suraj Shah
Todd Skacan
Yanay Ofran
Zack Scott
Zhen Su

Debtors' Professionals
Akin Gump Strauss Hauer & Feld LLP
B. Riley Restructuring Services, LLC
Grant Thornton, LLP
Murphy & King
Pashman Stein Walder Hayden, P.C.
Potter Anderson & Corroon LLP
Quinn Emanuel Urquhart & Sullivan, LLP
Kurtzman Carson Consultants, LLC (d/b/a Verita Global)
Walkers Global

Ordinary Course Professionals
Citrin Cooperman Advisors LLC
Covington & Burling LLP
Dechert LLP
Dennemeyer & Co., LLC
DiFilippo Corporate Finance Group
Elsberg Baker & Maruri PLLC
Maples Group

Marcum LLP (CBIZ, Inc.)
McNeill Bauer PLLC
Mishcon De Reya LLP (UK)
Ollie Yuav
Petra Funds Group, LLC
Pluris Valuation Advisors, LLC
Proskauer Rose LLP
Stout Risius Ross, LLC
WilliamsMarston LLC
Wilson Sonsini Goodrich & Rosati, P.C.

Rigmora Counsel
Debevoise & Plimpton LLP
Landis Rath & Cobb LLP

Portfolio Companies (aka non-debtor affiliates)
Aethon Therapeutics
Ascidian Therapeutics (fka Pulsar Bio Therapeutics)
Aulos Bioscience
Braeburn Inc.
Deep Apple Therapeutics
Galvaniz Therapeutics
Marengo Therapeutics
Replicate Bioscience

Management Debtors Top 20 Unsecured Creditors
Belay Solutions, LLC
Chelsea Technologies LLC
Cogent Communications, LLC
Echelon Fine Printing
Mark Mitchnick
RXR HB Owner LLC
The Agency Worldwide
The Regents of the University of California Berkeley

ATP Life Science Ventures, L.P. Equity Holders
Aaron Kantoff
Anna Batarina
Danjie (Eva) Zhou
David McIntyre
Hamade Family Trust (dated 6/18/2003)
Jonathan Waldstreicher
Julie A. Gionfriddo
Les Pommes LLC c/o/ Apple Tree Ventures Management LLC

Marie-Therese Afif
Paul Eisenberg
Rob Armstrong
Sally Jacob
Samuel Hall
Seth L. Harrison
Stephen G. Dance
The Lauren A. Farrell Trust (dated 5/18/2018)
William Engels

ATP III GP, Ltd. Equity Holder
Seth L. Harrison, MD

Red Queen Therapeutics, Inc. Top 20 Unsecured Creditors
Altasciences Company Inc.
Dechert LLP
Omega Systems Consultants
Omnicia, Inc.
Pace Analytical Life Sciences, LLC
Prendio LLC
Sarah Recchio

Red Queen Therapeutics, Inc. Equity Holders
Dana-Farber Cancer Institute, Inc.
Gregory Bird
Henry Herce
Loren Walensky
Marilynn Bersoff
Mark Mitchnick
Namrata Turaga
Paul Da Silva Jardine
Paul Eisenberg
Ravneesh Sachdev
Spiros Liras

Red Queen Therapeutics, Inc., Creditors
1Life Healthcare Inc.
9375-3408 Quebec Inc.
ADP, Inc
Amnet Systems LLC
Apple Tree Life Sciences, Inc.
Aptar Congers
Arthur J. Gallagher Risk Management Services, Inc.
Aruna K. Subramanian

Ascidian Therapeutics, Inc.
ATP Research and Development, Inc.
Bachem Americas, Inc.
Bay Valuation Advisors, LLC
BDO USA, LLP
Bend Financial, Inc.
Bill.com
Blue Cross Blue Shield
Boston Industries, Inc.
Brex
Browne Consulting Group
Cambridge Biolabs
Cambridge Trust
Cameron Wolfe
CD Chunn & Associates, Inc.
Charles River Laboratories, Inc.
Chien-Te Kent Tseng
Colorado State University
CPC Scientific, Inc.
Creative Biolabs Inc.
Credit Card Misc.
CT Corporation
Custom NMR Services, Inc.
Cytel Inc
Davey Smith
Delaware Secretary of State
Digital Insurance LLC
DocuSign, Inc.
Ea Spry Co. Inc.
eCtd Publishing LLC
Eric Smith
Eurofins Panlabs Discovery Services Taiwan, Ltd.
Eurofins Panlabs Inc
Eva Garland Consulting
EyeMed
Fragomen, Del Ray, Bernsen & Loewy, LLP
Franchise Tax Board
Gyros Protein Technologies
Halloran Consulting Group
Hansol Jang
Human Predictions LLC
ImQuest BioSciences
InCSD, LLC
Integral Molecular, Inc.

Intuit
IVEK Corporation
Janet Nokleby
John George McHutchison
JTR & Associates, LLC
K P'Das Bio-Consulting
KOC Consulting, LLC
Kyinno Biotechnology Co., Ltd.
Larry Smith
Latham BioPharm Group
LinkedIn Corporation
Loxley LLC
Lytica Therapeutics, Inc.
M3 USA Corporation
MED Regulatory & Toxicology Consulting, LLC
Medizinische UniversitÃt Innsbruck
Meeting Protocol Worldwide LP
Meeting Protocol Worldwide LP-1
Microbiologics
NAGASE Specialty Materials NA LLC
Nanopharm Ltd.
Nanopharm Ltd. – USD
Next Breath
Organix
Peak Scientific Inc.
Pentagram Design Inc.
PPD Development, LP
ProPharma Group LLC
Protein Technologies, Inc.
Prudence Ciardullo
PurePEG, LLC
Quality Compliance Partners, Inc.
Raphael J. Landovitz
Retrovirox Inc.
RG Supply Chain Consulting Inc
Ron Moss
Shelterpoint
Shyam Kottilil
Sigmovir Biosystems Inc.
Sino Biological US Inc.
Solium Capital LLC
Southern Research Institute
Spences Services LLC
Sterling Corporation

Sun Life
The Agency Worldwide
The Catalytic Agency, LLC
Tremaine DMPK Consulting, LLC
True North Biopharm LLC
TS Pharma Experts LLC
Tufts Biolabs
University of Tennessee Health Science Center
Uppsala Monitoring Centre
Utah State University, Institute for Antiviral Research
V4Scientific
Vascumab LLC
Vectura Ltd.
ViraTree LLC
Vivitide
Waters Technologies Corporation
World Courier Inc
World Customs Brokerage Inc
WuXi AppTec (HongKong) Limited
YIN HTWE
Zahra Fathi

Initial Therapeutics, Inc. Top 20 Unsecured Creditors

Airgas USA, LLC
Armanino Advisory LLC
BDO USA LLP
CAS Chemical Abstract Services, Inc.
Curia Global, Inc.
Diamond Age Data Science LLC
Fisher Scientific Company, LLC
Forkable
Formulatrix LLC
Life Technologies Corporation
Mettler-Toledo Rainin, LLC
NexusCW Inc
Pegasus Purchaser, Inc.
Pharmaron, Inc.
Promega Corporation
ProteinSimple Checking BIN #39
Stemcell Technologies Inc
Tecan U.S. Inc
VWR International, LLC

Initial Therapeutics, Inc. Equity Holders

Alexander McCampbell
Brain Paegel
Brooke Olsen Blair
Danielle Carino
Fred Ward
Ilsa Kirby
James H. Doudna Cate
James and Jennifer Doudna Cate Living Trust (dated 1/2/2014)
Kevan Shokat
Kevan M. Shokat and Deborah Kamali, as trustees of the Shokat-Kamali Living Trust (dated 5/11/2012)
Margot Paulick
Mariwil Wong
Matthew Jacobson
Micheal Ehlers
Mohan Sivaraja
Mohit Trikha
Neena Kadaba
Peiwen Yu
Peter DiLaura
Phil Patten
Rachel Green
Rajesh Chopra
Sarah Smith
Spiros Liras
Stephanie Maiocco
Xiaoyue (April) Chen

Initial Therapeutics, Inc., Creditors
1Life Healthcare, Inc.
201 Spear Street
AA BLOCKS, LLC
AABC Testing & Certification
AACR
ABBEXA
Abcam, inc.
AC Hotel
AC Lab Instruments
Ace Parking
Acrotien ChemBio Inc
ACTenviro
Adobe
ADP
Agilent Technologies, Inc.

AIR-TITE Products Co., Inc.
AK Scientific, Inc.
Alaska Airlines
Alex's Mobile Notary Public Services
Alithea Genomics SA
Allucent US LLC
Alpha Teknova, Inc.
Amami San
Amaresh Keleta
Amazon
Amazon Business Prime
Amazon Capital Services, Inc.
Amazon Web Services
Ambeed, Inc.
American Association for Cancer Research
American Chemical Society
American Type Culture
American Type Culture Collection
Amith Vikram Rangarajan
Amoura Resturant
Ampersandpeople inc
Anecdote
Anirban Datta
Ann MacLaren
Antibodies Inc.
AnytimeLabTrader, LLC
Aon Consulting, Inc. (NJ)
Apconix Ltd.
Apertor Pharmaceuticals Inc.
Apexbio Technology LLC
Apicells Inc.
Are Café Resturant
Arthur Dean Olson (Dean Olson Patent Consulting)
Arthur J. Gallagher Risk Management Services, Inc.
Asana
ASCO
AstaTech Inc.
Astrill VPN
ATCC
ATP Research and Development, Inc.
Atum
Aurigene Pharmaceutical Services, Ltd.
Avanan
Aviva Systems Biology

Axis Enterprises Inc.
Axis Promotions
Azenta US, Inc.
Backhaus
BambooHR
Baskin-Robbins
Bay Valuation Advisors
Bayshore Safety & Industrial Supplies
BCBS
Beckman Coulter, Inc.
Becton, Dickinson & Co.
Bend Financial
Biocom California
BioDuro LLC
BioIVT
BioLegend
BioProcedure
Bio-Rad Laboratories, Inc.
Biospace
Biotage, LLC
Biotech Equipment Sales, Inc.
Bio-Techne Sales Corporation
Bliss Pops
Blossom Flower Deliver
Blue Bottle Coffee
BMG LABTECH, Inc.
Bordelon Marine
Boster Biological Technology
Box, Inc.
BPS Bioscience Technology
Brady Worldwide Inc
Brex Card – Expensify Linked
Brian Benjamin Tuch
Bridge Bank
Broken Yolk Café
Bronwyn Sanders
Browne Consulting Group
BUTCHER'S CUT
Cable 55
Caffe Central
Caffe Centro
California Chamber of Commerce
California Franchise Tax Board
California Pizza Kitchen

Cambridge Healthtech Institute
Cancer Research Institute
CC My Admin LLC
CDW LLC
Celine Calalang
Cell Culture Company
Cell Signaling Technology, Inc.
Certara USA, Inc.
Certified GeneTool, Inc.
Champions Oncology, Inc.
Charles Kreider (Kreider Consulting)
Charles River Laboratories
Chase Luck Bakery
Checkr
ChemAxon
ChemExplorer Company LTD
Chemglass Life Sciences
Chemical Computing Group
Chemrus Inc.
Che,scene Limited Liability Company
Chemtos LLC
Chico Marx
Chipotle Online
Christine Matthews (now Digital Insurance)
Christos Tzitzilonis
Chwen Cheng Chen
Cintas Corporation (AZ)
City of Burlingame
City of Sm Pw Parking
City of South San Francisco
City of Ssf Permit Dept
Clarke Consulting
Clarke S1 Sirn
Clipper
CLSA
CAN
Collaborative Drug Discovery, Inc.
Combi-Blocks Inc.
Computer Care
Copyright Clearance Center
Corovan Moving & Storage Co.
Costco
Creative Biogene, Inc.
Creative Biolabs, Inc.

Credit Card Misc.
Crossmint Pending
Crown Bioscience Netherlands BV
Crown Bioscience, Inc.
Crown Worldwide Moving and Storage, LLC
CSC
CSC Leasing CO
Cshl Meetings & Courses
CT Corporation
Culligan
Culligan Water
Curia Bio Inc. (dba Lake Pharma)
Cursor
CVS Pharmacy
Daicel Chiral Technologies
Danae Inc.
Daniel W Pierce
Data Kable Technology Inc
Dataworks Development Inc
DC3 Therapeutics, LLC
De Novo Software
Dead Eye Coffee Bar
Dean W. Felsher
Deep Apple Therapeutics, Inc.
Delaware State
DeNoix Inc
DHL
Diaago LLC
Dice Molecules SV, inc.
Divisadero Florist
DocuSign
Dojindo Molecular Technologies, Inc.
Dollar Tree
Donald Schmidt Jr.
DoorDash
Dorothy Rachel Green
Dotmatics, LLC
Dragonfly Design Group
Drug Design Group
Easy Learning Incubator LLC
EasyLlama
Eataly
eBay
EDITCO BIO INC.

Edward M. Driggers
Eirna Bio Ltd
Embassy Suites by Hilton
EMD Millipore Corporation
Emily Lin Karbarz
eMolecules, Inc.
Enamine US Inc.
Endpoints
Envoy
Eppendorf North America Inc.
Esposto's Catering
Esquire
Esraa Mohamed
Etsy
Eurofins Cerep SA
EUROFINS DISCOVEREX CORP
Eurofins Panlabs Inc.
EventCreate
Express Parking
Extra Space Storage
EyeMed
ezCater
Ezcater Ruse Woodfire
Farley's
FedEx
FlowJo LLC
Fragomen, Del Ray, Bensen, & Loewy, LLP
Frontage Laboratories, Inc.
Frontier Scientific Services Inc.
Fuchunju
FUJIFILM Wako Chemicals U.S.A. Corporation
G&P Biosciences LLC
Galen Laboratory Supplies LLC
GarboBio Inc. (AcceGen)
Gary F. Musso
Gaslamp
GeneCopoeia, Inc.
Genesee Scientific Corporation
GenScript USA, Inc.
Gifford Bioscience Ltd
Github
GlobalData
GoDaddy
Gordon Rees Scully Mansukhani, LLP

Grainger Industrial Supply
Grant Park Bistro
GraphPad
Greenhouse Software, inc.
GroupGreeting
GS Pharma Solutions, LLC
Hamamatsu Corporation
Headline Pa
Herb N' Kitchen
High Flying Foods
Hilton Hotels
HL Peninsula
HoneyBaked Ham
Horizon Discovery Biosciences Ltd
Hyatt
Ichika Sushi House
IKA-WORKS, Inc.
IKEA
Il Fornaio
Illumina, Inc.
Impark
India Quality Restaurant
Indian Clay Pot
Instacart
Integra Biosciences Corporation
Integrated DNA Technologies, Inc.
Integrative Drug Discovery ULC
Intuit
Invested Digital Group, Inc.
IQ Proteomics, LLC
Jack in the Box
Jackie McGrath Inc.
Jeff Hsu
Jena Bioscience GmbH
Jennifer Rocnik
Jessamyn Wead
Jetbrains Americas, Inc.
Jim Li
JMP Group Inc.
John Hood
Jonathan R Wong dba Enigma Search Solutions LLC
Joesph M. Llovet
Joesph Fan
Julius Khoo, Consultant

K.F. Howell Electric, Inc.
Kai Fa Qu Xi Lai Deng Jiu
Kenneth B. Wlasichuk
Kim F. McClure (Kb Pharma Consulting, LLC)
Klein Hersh International
Kristina Leandra Harter
Kristine Anne Gordon
Laurie L. LeDoux
LAZ Parking
Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Lenovo Group
Letterman Digital Arts
LifeSpan Biosciences, Inc.
Lonza Walkersville, Inc.
Lowe's
Lucid Software
Luke's Lobster
Marriott
Marshall Scientific LLC
Martin S. Linsell
Maruzen International Co., Ltd.
Matphil Technologies, Inc. dba Pipette.com
McCormick Place
McMaster-Carr Supply
McNeill Baur PLLC
Meaghan An
MeCour Temperature Control, LLC
MedChemExpress LLC
Mercury Business Services LLC
Meso Scale Diagnostics, LLC
Metrion Biosciences Ltd.
Mzez Greek Fusion
Microsoft Office Azure
Microsoft Store
Miller & Lux Restaurant
MingHin Cuisine
Molecular Devices, LLC
MongoDB
Monnit Corporation
Moravek Biochemicals, Inc.
Morrow Service, Inc.
Mosaic Networx, LLC
Murigenics, Inc.
Murphy & King

MyBioSource, Inc.
NanoImaging Services, Inc.
Nanosyn, Inc.
National Screening Services LLC
Nationwide Screening Services
Nespresso
New England Biolabs
Nicholas Galli
Niu B
NorCal Water
Nothing Bundt Cakes
Novogene Corporation Inc.
NovoPro Bioscience Inc.
Novus Biologicals, LLC
Nuaire
NXT Power, LLC
Occupational Health Centers of North Carolina, P.C.
Okta, Inc
OLIVAS MEXICAN FOOD
On The Roll Catering and Events
One12
OneDigitial Topco LLC (Digital Insurance LLC)
OpenAI
Optibrium Limited
OriGene Technologies, Inc.
Osteria Panevino
Palace Hotel Dining
Panera Bread
Parking – SF
Parr Instrument Company
Pbss
Penske Truck Rental
PerformYard, Inc.
Peter DiLaura
Pharmablock (USA), Inc.
Phenomenex, Inc.
Pingyu Ding
Pizzeria Delfina
Plasmidsaurus Inc.
Posit Software, PBC
Postal Annex
Prendio LLC
Pressed Café
Prestige Lens Lab

PricewaterhouseCoopers LLC
Primordium Labs
Prince Scientific LLC
Profcontrol GmbH
Pronto!
Proteintech Group, Inc.
Qiagen LLC
Quintara Discovery, Inc.
R&D Systems, Inc.
Rachel Kindt
Ramen Hero
RayBiotech
RC TRITEC AG
Regents of the University of CA, Irvine
Remarkable
RevMAb Biosciences USA, Inc.
Revvity Health Sciences, Inc.
Revvity Signals Software, Inc.
Rhino Networks
Ribomaps LTD
Ricky P Jones
RIPOSO
Riposo Mobile
Road Master Club
Ronnie-Ray Abriam Orpilla
Rosemarie O'Shea
RStudio
Rudra Nand
Russell Reynolds Associates, Inc.
Sab Lai Thai Kitchen
Samuel Munroe
San Diego Convention Center
San Francisco Baking Institute
San Francisco International Airport
San Mateo County
San Mateo County Tax
Santa Cruz Biotechnology Inc
Sartorius Corporation
SBC Worldwide, LLC
Schrodinger, LLC
SciSummary
Secretary of State California
See's Candies
Seismic Installations

Selleck Chemicals LLC
Sensitech Inc.
Sentinel
Seqmatic LLC
SFMTA Parking
Shanghai Chempartner Co., Ltd.
Sheridan Books
Shisan Fan Sushi and Chinese Restaurant
Shred City
Sigma-Aldrich, Inc.
Signal Solutions Corporation
Silicon Valley Corporate Relocation
SL 2T, LLC (SmartLabs)
Slack
Slidexpress PVT LTD
SmartSign
SnapGene
SNPsaurus
Solium Plan Managers LLC
Soloprotect US
SPRO
Stanford University
Staples
Staples Advantage
Starbucks
Stella Alpina Osteria
Stericycle, Inc.
Steven A Smith
Steven J. Freedman
Steven R. Sando
Strategic Spaces
Subscription Cc Auth
Sun Life Financial
Surplus Solutions LLC
Susan Lyman
Susanne Steggerda
Swagelok Northern California
Synthego Corporation
System Biosciences
TAQUERIA LAS PENCAS
Target
Tastes On The Fly
Tax1099
TeamViewer

Technical Safety Services, LLC
Technology & Patent Research International, Inc.
Teledyne ISCO
Thai Satay Restaurant & Bar
The Agency Worldwide
The Catalytic Agency, LLC
The Cohen Group
The Grove Wine Bar & Kitchen - Cedar Park
The Home Depot
The Honest Company
The Regents of the University of California, San Francisco
The Speech Improvement Company Inc.
Therma LLX
Thomas Scientific Holdings Inc
Thorlabs, Inc.
Tim French
Total Wine & More
Traverse
TriLink Biotechnologies, LLC
Trip.com
Triton Appliance Repair
Uber
Uline, Inc
United
Unity Biotechnology
University of California, San Diego Small Molecule X-ray Crystallography Facility
UPS Supply Chain Solutions, Inc.
Urban Kitchen
USA Scientific, Inc.
USPS
Vector Laboratories, Inc.
Veloxee
Vincor Tech
Vistaprint
W.B. Mason Company, Inc.
W.W. Grainger, Inc.
Waterco of California
Wave
Wave Rock
West Coast Chemistry Services
White Elephant Restaurant
Whole Foods Market
Wise Guys Events
WPP Group USA, Inc. dba Ogilvy Health

WTMR
WuXi AppTec (Shanghi) Co., Ltd.
Yi Chao Fan
Yummy Home Plate
Zachary Sweeney (Edgewood Scientific Consulting)
Zazzle
Zoom Video Communications, Inc.
Zotero
Zymo Research Corporation

Marlinspike Therapeutics, Inc. Top 20 Unsecured Creditors
Advion, Inc.
Air Systems Technologies Inc
Aurigene Pharmaceutical Services LTD
Baylor College of Medicine
BDO USA, LLP
BioProcure, Inc.
Biotech Law Center, Inc.
Browne Consulting Group
Crown Castle International Corp.
CSC Leasing Co
Digital Insurance, LLC
Middlesex Gases & Technologies, Inc.
Norton Rose Fulbright US LLP
Pharmaron, Inc.
PPF OFF 150
Roger Benjamin Ruggeri
Safety Partners
Triumvirate Environmental, Inc.
Viva Biotech (Shanghai) Limited

Marlinspike Therapeutics, Inc. Equity Holders
Alessandro Boezio
Alexander McCampbell
Baylor College of Medicine
Calla Olson
Joesph Yanchik
Kristen Karlin
Paul Da Silva Jardine
Rajesh Chopra
Thomas Westbrook
Victor Rusu

Apertor Pharmaceuticals, Inc., Top 20 Unsecured Creditors

1640 South Loop Road LLC c/o Paceline Investors LLC
Alameda County Tax Collector
Benchling, Inc.
BioDuro, LLC
BioProcure, Inc.
Browne Consulting Group
Cell Signaling Technology, Inc.
Clarke Consulting, Inc.
CSC Leasing Company
De Lage Landen Financial Services, Inc.
Digital Insurance, LLC
Elsevier B.V.
IQ Proteomics, LLC
Laboratory Equipment Company
Life Technologies Corporation
Reaction Biology Corporation
Science Suite Inc. dba BioRender
University of North Carolina at Wilmington
Zhejiang Huida Biotech Co., Ltd.

Apertor Pharmaceuticals, Inc. Equity Holders
Bo Pang
Daniel Nomura
Edmund Graziani
Ericka Mendez
Jay Keasling
Jay D. Keasling Trust (Dated 8/5/2013)
Kevan Shokat
Lawrence Lum
Matthew Jacobson
Micheal White
Neena Kadaba
Paul De Silva Jardine
Paul Eisenberg
Paul Hawkins
Rajesh Chopra
Samantha Bucktrout
Shellwater & Company
Spiros Liras

Apertor Pharmaceuticals, Inc., Creditors
1Life Healthcare, Inc.
Abcam, Inc.
Abmole Bioscience Inc.

Abwiz Bio Inc
Access Plants LLC
Adams & Chittenden Scientific Glass
ADP
Advanced Chemical Transport
Agilent Technologies, Inc
AK Scientific, Inc.
Alameda County Environmental Health
Amazon Capital Services
Amazon Web Services
Ambeed Inc.
AmiD Biosciences LLC
AnaSpec Inc.
Apple Tree Life Sciences, Inc.
Applied Chemistry Solutions
Applikon Biotechnology, Inc.
Arash Samadi
Arthur J. Gallagher Risk Management Services, Inc.
ATCC
Atlas Copco Compressors LLC
ATP Research and Development, Inc.
Avanan, Inc
AxisPharm
Azenta US, Inc.
Bay Air Systems
Bay Valuation Advisors, LLC
BCBS MA
BDO USA, LLP
Becton, Dickinson and Company
Bend Financial, Inc.
Bill.com
Bio Basic Inc.
bioauxilium
Biocair Inc
BioLegend, Inc.
Biomatik Corporation
BioPharmics LLC
Bio-Rad Laboratories, Inc.
Biotage LLC
BiotechnologyJobs
Biozilla, LLC
Bordelon, Inc dba Ben’s Dry Ice
Boston BioProducts, Inc.
BPS Bioscience, Inc.

Brex
BroadPharm
BUCHI Corporation
California Fire Detection
California Life Sciences
Carvill Consulting
Cayman Chemical Company Inc.
CC My Admin, LLC
CDW Direct, LLC
Cell Biolabs, Inc.
Charles River Discovery Research Services UK Limited [GBP]
Charles River Discovery Research Services UK Limited [USD]
Charles River Laboratories Cell Solutions, Inc.
Chemglass Life Sciences, LLC
Chemical Computing Group
Christian Puccetti
Chun Li
Cintas Corporation
Clarivate Analytics (US) LLC
Clark + Elbing LLP
CNA
Cole-Parmer Instrument Company, LLC
Collaborative Drug Discovery, Inc.
Combi-Blocks Inc.
Comcast
Commonwealth of Massachusetts
ComputerCare, LLC
Cooley LLP
Copyright Clearance Center, Inc.
CozChemix Limited
Creative Bioarray
Creative BioMart Inc.
Credit Card Misc.
CT Corporation
CTK Instruments LLC
Data Kable Technology Inc
Dean Olson Patent Consulting LLC
Demetrix, Inc.
Denisse Martinez
Diaago LLC
Diego Garrido Ruiz
Discovery Life Sciences
Discovery Scientific Solutions LLC
Diversified Laboratory Repair, Inc.

Dragonfly Design Group, Inc.
E-Control Systems, Inc.
Elson Electric
Epoch Life Science, Inc.
Eppendorf North America, Inc.
Esco Technologies, Inc.
EyeMed
Fahim Syed
FedEx Freight
First Choice Coffee Services
Fisher Scientific
Flowjo, LLC
Fortis Life Sciences fna Bethyl Laboratories
Foxx Life Sciences, LLC
Fragomen, Del Ray, Bernsen & Loewy, LLP
FUJIFILM Wako Chemicals U.S.A. Corporation
Genesee Scientific Corporation
Genewiz, LLC
Genprice Inc.
GenScript USA Inc.
Gentige USA Sales, LLC
Global Industrial
Global Life Sciences Solutions USA LLC
Gold Biotechnology
Gordon Research Conferences
Grainger
GSL Biotech, LLC
Hamilton Company, Inc.
Harris & Lee Environmental Sciences LLC
HARVARD APPARATUS
Heather Roth
Hooke Laboratories, Inc.
HIS
ICE Safety Solutions
IKA Works, Inc.
Independent Plumbing Co.
Infors USA Inc.
Ingenium Group, LLC
Initial Therapeutics, Inc.
Integra Biosciences Corporation
Integrated DNA Technologies, Inc.
Intuit, Inc
Invested Digital Group, Inc.
Iron Box LLC

Isomerase Therapeutics Ltd
James Kim
Jeff Wong
Jeremy Barton Consulting Inc.
Karen Sutherland
KBA Document Solutions, LLC
Kelly Services
Labelmaster
LABRepCo LLC
Lambda
Lawson Drayage, Inc
Leibniz- Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Leo Letendre
LHE Bioscience Inc.
LI-COR Biotech, LLC
LI-COR, Inc.
Linde Gas & Equipment Inc.
Litmos US, L.P. f/k/a Solo Operations US, LLC
Lonza Walkersville, Inc.
Mallory Safety and Supply LLC
Marmon Biostatistics
Marvelgent Biosciences, Inc.
McMaster-Carr
MedChemExpress, LLC
MedSupply Partners
Mettler-Toledo Rainin, LLC
Mettler-Toledo, LLC
Microverse Studios
Molecular Devices
Mosaic Network
Nacalai USA, Inc.
Naomy Jareily Ruvalcaba
National Institute of Technology and Evaluation
Nationwide Screening Services
NBS Scientific, LLC
NCS Moving Services
Nefeli Chanoutsi
Neil Vasan
New England BioLabs, Inc.
New Life Scientific, Inc.
New Pig Corporation
North America Immigration Law Group
Novogene Corporation Inc.
Novus Biologicals, LLC

NW Seacology
NXT Power
Okta, Inc.
OTJ Architects
Oxford Nanopore Technologies Inc.
Peak Scientific, Inc.
Pete KOH Installations
Phenomenex, Inc.
Plasmidsaurus
Prenido LLC
Prestige Lens Lab
PricewaterhouseCoopers LLP
Promega Corporation
ProPharma Group LLC
Protection Plus Security Services
Proteintech Group, Inc.
Qiagen LLC
QuakeHold Industrial, Inc.
R&D Systems, Inc.
Rabin
Raissa Estrela Curado
Ray Liu Consulting LLC
Regina Roodhouse
Revvity Health Sciences, Inc.
Revvity Signals Software, Inc.
Roman Aguirre
Rose Citron
San Mateo County Tax Collector
Sandra Santulli-Marotto
Santa Cruz Biotechnology, Inc.
SBS Pharma Consulting
Sciencelo
Scientific Plastics Company, Inc.
SciSafe Inc.
Seismic Installations
Sentinel Benefits
SeqCenter
SEQUETECH CORP
Sequoia Signs & Graphics, Inc.
SFS Chemical Safety
Shimadzu Scientific Instruments, Inc.
Shinji Kasahara
Sigma-Aldrich, Inc.
Signalchem Biotech Inc.

Signosis, Inc.
Silas Burdick
Sino Biological US inc.
SL2T LLC
SmartSheet Inc.
SNPsaurus LLC
Solium Plan Managers LLC
SoloProtect US LLC
South San Francisco Fire Department
Southern Biotech
Staples Advantage
State of CA – Franchise Tax Board
State of Delaware – Division of Corporations
Stemcell Technologies Inc
STERIS Corporation
Strategic Spaces, LLC
STRUCTURAL ENGINEERS, INC.
Sun Life Assurance Company of Canada
Takara Bio USA, Inc.
Technical Safety Services, LLC
Teco Pneumatic
Tenova Pharmaceuticals Inc.
Thames Pharma Partners, LLC
The Cambridge Crystallographic Data Centre
The Cohen Group
The Ogilvy Group LLC
The Regents pf the University of California
Thermo Fisher Financial Services Inc.
Thomas Scientific, LLC
Tinghua Cao
Toronto Research Chemicals, Inc.
Tracking Solutions, Inc.
Twist Bioscience Corporation
Uline, Inc.
US Bank Equipment Finance
USA Scientific
Varigen Biosciences
Vascumab LLC
Veolia Water Technologies, Inc.
VWR International LLC
William A. Faubion, M.D.
Wuxi AppTec (HongKong) Limited
Wynden Stark LLC
XanTec bioanalytics GmbH

Zymo Research Corporation

Evercrisp Biosciences, Inc. Top 20 Unsecured Creditors
Admera Health, LLC
Agilent Technologies, Inc.
BioMetas Group Limited
Browne Consulting Group
Charles River Laboratories, Inc.
ChemPartner Corporation Chengdu ChemPartner Co., Ltd.
CSC Leasing Company
Digital Insurance, LLC
Fisher Scientific
Global Project Partners, LLC
Horizon Discovery Biosciences Ltd
Life Technologies Corporation
Marija Zecevic
Pegasus Purchaser Inc., - BioProcure LLC
Robert Thomas Abraham
Tanja Kortemme
VWR International, LLC
Wuxi AppTec (HongKong) Limited

Evercrisp Biosciences, Inc. Equity Holders
Ajeeth Adhikari
Benjamin Jagger
Brian Vash
Cody Krivacic
Geoffrey Berguig
Jennifer Doudna
Matthew Jacobson
Meenu Karson
Neena Kadaba
Peng Cheng Zhang
Raj Chopra
Spiros Liras
Stephanie Maiocco
Steven Strutt
Victor Rusu

Nine Square Therapeutics, Inc. Top 20 Unsecured Creditors
Amazon Web Services
Amprion, Inc.
Biognosys AG

Browne Consulting Group
CAS
Cell Signaling Technology, Inc.
FUJIFILM Cellular Dynamics, Inc.
Hooke Laboratories, LLC
Institut Curie
LeadTech Pharma, Inc.
Life Technologies Corporation
Mettler-Toledo Rainin, LLC
Pegasus Purchaser, Inc. (BioProcure)
Pharmaron
PLANET PHARMA, LLC
Regents of the University of Michigan
Revvity Health Sciences, Inc.
Viva Biotech (Shanghai) Limited
Wuxi AppTec United

Nine Square Therapeutics, Inc. Equity Holders
Aimee Kao
Alexander McCampbell
Brina Le
Chakrapani Kalyanaraman
Damoder Motati
Hoi-Shan (Helen) Wong
Jacob Meller Eriksen
James Summers
John Hood
Kristine A. Gordon
Lani Wu
Louise Heinrich
Mark Rosen
Matthew Jacobson
Micheal Ehlers
Neena Kadaba
Paul Da Silva Jardine
Robert Edwards
Robert Paul
Roberto Zoncu
Sami Barmada
Samuel Clark
Sarah Smith
Spiros Liras
Steven Altschuler
Tetsuya Kobayashi

Tina Schwabe

Rigmora LPs
Rigmora Biotech Investor One LP
Rigmora Biotech Investor Two LP

Nereid Therapeutics Equity Holders
Alex McCampbell
Alice Ting
Bahareh Eftekharzadeh
Chanelle Jumper
Cigall Kadoch
Dr. Clifford Brangwynne
Eugine Lee
Defne Yarar
Ivan Efremov
Jared Toettcher
John Reilly
Dr. Laura Forese
Matthew Jacobson
Robert Hugin
Spiros Liras

Nereid Therapeutics Top 20 Unsecured Creditors
Amnet Systems, LLC
AustinPX LLC
Beckman Coulter, Inc.
BioDuro, LLC
Crelux GmbH
Crystal Pharmatech Co., Ltd.
Eurofins Panlabs Inc.
Evotec US
Life Technologies Corporation
Nexomics BioSciences
Oncolines
Premier Research Consulting, LLC Reaction Biology Corporation
RREF II 451D, LLC
Schrodinger, LLC
STA Pharmaceutical Hong Kong Limited
VectorBuilder, Inc.
Viva Biotech (Shanghai) Limited
Wuxi AppTec

SCHEDULE 2[1]

Disclosures of Orrick, Herrington & Sutcliffe LLP[2]

Party in Interest	Connection to Debtors[3]	Connection to Orrick[4]
1Life Healthcare Inc.	Red Queen Therapeutics, Inc., Creditors	Current Client Affiliate
1Password	CONTRACT COUNTERPARTIES	Current Client
230 Park Avenue Holdco, LLC	LESSORS	Current Client Affiliate
Abcam, inc.	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
AC Hotel	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Ace Parking	Initial Therapeutics, Inc., Creditors	Firm Vendor
ACTenviro	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Adobe	Initial Therapeutics, Inc., Creditors	Former Client; Firm Vendor
ADP	Initial Therapeutics, Inc., Creditors	Current Client Affiliate

[1] The Potential Parties in Interest listed herein include individual persons and, in many cases, Orrick does not have sufficient information to verify whether they are the same individuals that are current or former clients or representatives of clients of Orrick on matters unrelated to these Chapter 11 Cases or different individuals that share the same name. Out of an abundance of caution, Orrick has erred on the side of being overly inclusive by assuming that such individuals are the same persons for purposes of the disclosures contained herein.

[2] The parties listed herein are Potential Parties in Interest (or affiliated entities) who are current clients or vendors or insurance carriers of Orrick or were clients of Orrick within the last three (3) years. The disclosure of affiliate relationships among potentially related entities reflects only information known to Orrick through its conflict reporting system. Orrick has not performed independent research to identify other affiliate relationships with respect to the parties on the Debtors' Interested Parties List.

[3] This schedule is for disclosure purposes only and uses the Debtors' description of the relationship to the Debtors, where available. The Fund Debtor expressly reserves all rights, including, without limitation, to the nature, extent, and validity of any party's alleged lien or claim.

[4] Those parties in interest that are current clients of Orrick's are involved in matters substantially unrelated to these Chapter 11 Cases.

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
ADP, Inc	Red Queen Therapeutics, Inc., Creditors	Current Client Affiliate
Advanced Chemical Transport	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Agilent Technologies, Inc	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Agilent Technologies, Inc.	Initial Therapeutics, Inc., Creditors	Current Client
Alameda County Environmental Health	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Alameda County Tax Collector	Apertor Pharmaceuticals, Inc., Top 20 Unsecured Creditors	Current Client Affiliate
Alvarez & Marsal Holdings LLC	DEBTOR'S PROFESSIONALS	Current Client; Firm Vendor
Amnet Systems, LLC	Nereid Therapeutics Top 20 Unsecured Creditors	Current Client Affiliate
Anecdote	Initial Therapeutics, Inc., Creditors	Current Client
Antibodies Inc.	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Aon Consulting, Inc. (NJ)	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Applikon Biotechnology, Inc.	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Asana	Initial Therapeutics, Inc., Creditors	Current Client; Firm Vendor
ASCO	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
ATP Research and Development, Inc.	Red Queen Therapeutics, Inc., Creditors	Current Client Affiliate

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Atum	Initial Therapeutics, Inc., Creditors	Current Client
Avanan	Initial Therapeutics, Inc., Creditors	Current Client
Avanan, Inc	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Azenta US, Inc.	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Backhaus	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Banc of California	BANKS	Current Client
Barry Lynch, as Official Liquidator	CAYMAN APPOINTED OFFICEHOLDERS	Former Client
Baskin-Robbins	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
BCBS	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
BDO USA LLP	Initial Therapeutics, Inc. Top 20 Unsecured Creditors	Former Client Affiliate
BDO USA, LLP	Red Queen Therapeutics, Inc., Creditors	Former Client Affiliate
Beckman Coulter, Inc.	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Becton, Dickinson & Co.	Initial Therapeutics, Inc., Creditors	Current Client
Becton, Dickinson and Company	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Bend Financial	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Bend Financial, Inc.	Red Queen Therapeutics, Inc., Creditors	Current Client Affiliate

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Bill.com	Red Queen Therapeutics, Inc., Creditors	Current Client
Biocom California	Initial Therapeutics, Inc., Creditors	Firm Vendor
BioDuro LLC	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
BioDuro, LLC	Apertor Pharmaceuticals, Inc., Top 20 Unsecured Creditors	Current Client Affiliate
Biognosys AG	Nine Square Therapeutics, Inc. Top 20 Unsecured Creditors	Current Client Affiliate
BioLegend	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
BioLegend, Inc.	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Biotage LLC	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Biotage, LLC	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Blue Cross Blue Shield	Red Queen Therapeutics, Inc., Creditors	Current Client Affiliate
BMG LABTECH, Inc.	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Boston Industries, Inc.	Red Queen Therapeutics, Inc., Creditors	Former Client Affiliate
Box, Inc.	Initial Therapeutics, Inc., Creditors	Current Client; Firm Vendor
Braeburn Inc.	PORTFOLIO COMPANIES - NON-DEBTOR AFFILIATES	Current Client

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Brex	Red Queen Therapeutics, Inc., Creditors	Current Client
Brex Card – Expensify Linked	Initial Therapeutics, Inc., Creditors	Current Client
Bridge Bank	Initial Therapeutics, Inc., Creditors	Current Client
California Franchise Tax Board	Initial Therapeutics, Inc., Creditors	Current Client Affiliate; Former Client ; Firm Vendor
California Life Sciences	Apertor Pharmaceuticals, Inc., Creditors	Firm Vendor
Cambridge Healthtech Institute	Initial Therapeutics, Inc., Creditors	Firm Vendor
Cameron Wolfe	Red Queen Therapeutics, Inc., Creditors	Firm Vendor
Canon	VENDORS	Current Client
CAS	Nine Square Therapeutics, Inc., Top 20 Unsecured Creditors	Current Client Affiliate
CDW Direct, LLC	Apertor Pharmaceuticals, Inc., Creditors	Former Client; Firm Vendor
CDW LLC	Initial Therapeutics, Inc., Creditors	Former Client; Firm Vendor
Charles River Discovery Research Services UK Limited [GBP]	Apertor Pharmaceuticals, Inc., Creditors	Former Client Affiliate
Charles River Discovery Research Services UK Limited [USD]	Apertor Pharmaceuticals, Inc., Creditors	Former Client Affiliate
Charles River Laboratories	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Charles River Laboratories Cell Solutions, Inc.	Apertor Pharmaceuticals, Inc., Creditors	Former Client Affiliate

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Charles River Laboratories, Inc.	Evercrisp Biosciences, Inc. Top 20 Unsecured Creditors	Former Client Affiliate
Cintas Corporation	Apertor Pharmaceuticals, Inc., Creditors	Current Client; Firm Vendor
Cintas Corporation (AZ)	Initial Therapeutics, Inc., Creditors	Current Client; Firm Vendor
Citizens Bank	BANKS	Current Client
City of Burlingame	Initial Therapeutics, Inc., Creditors	Current Client
City of South San Francisco	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
City of Ssf Permit Dept	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Clarivate Analytics (US) LLC	Apertor Pharmaceuticals, Inc., Creditors	Firm Vendor
Clipper	Initial Therapeutics, Inc., Creditors	Current Client
CNA	Apertor Pharmaceuticals, Inc., Creditors	Current Client; Firm Insurer
Cogent Communications, LLC	MANAGEMENT DEBTORS - TOP 20 UNSECURED CREDITORS	Firm Vendor
Combi-Blocks Inc.	Initial Therapeutics, Inc., Creditors	Current Client
Comcast	Apertor Pharmaceuticals, Inc., Creditors	Firm Vendor
Commonwealth of Massachusetts	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate; Firm Vendor
Contemporary Information Company	LESSORS	Current Client

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Continental Casualty Company	INSURANCE PROVIDERS	Current Client
Cooley LLP	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Costco	Initial Therapeutics, Inc., Creditors	Current Client
Covington & Burling LLP	ORDINARY COURSE PROFESSIONALS	Firm Vendor
CPC Scientific, Inc.	Red Queen Therapeutics, Inc., Creditors	Current Client Affiliate
Crown Bioscience Netherlands BV	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Crown Bioscience, Inc.	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
CSC	Initial Therapeutics, Inc., Creditors	Current Client
CT Corporation	Apertor Pharmaceuticals, Inc., Creditors	Firm Vendor
Culligan	Initial Therapeutics, Inc., Creditors	Firm Vendor
Curia Bio Inc. (dba Lake Pharma)	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Curia Global, Inc.	Initial Therapeutics, Inc. Top 20 Unsecured Creditors	Current Client Affiliate
Cursor	Initial Therapeutics, Inc., Creditors	Former Client
CVS Pharmacy	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Dana-Farber Cancer Institute, Inc.	Red Queen Therapeutics, Inc. Equity Holders	Former Client

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
David Lewis	NON-DEBTOR PORTFOLIO COMPANY DIRECTORS AND OFFICERS	Former Client
De Lage Landen Financial Services, Inc.	Apertor Pharmaceuticals, Inc., Top 20 Unsecured Creditors	Current Client Affiliate
Debevoise & Plimpton LLP	RIGMORA COUNSEL	Current Client; Firm Vendor
Dechert LLP	Red Queen Therapeutics, Inc. Top 20 Unsecured Creditors	Current Client
Delaware Secretary of State	Red Queen Therapeutics, Inc., Creditors	Firm Vendor
Delaware State	Initial Therapeutics, Inc., Creditors	Firm Vendor
DHL	Initial Therapeutics, Inc., Creditors	Former Client
Dice Molecules SV, inc.	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Digital Insurance LLC	Red Queen Therapeutics, Inc., Creditors	Current Client Affiliate
Digital Insurance, LLC	Evercrisp Biosciences, Inc. Top 20 Unsecured Creditors	Current Client Affiliate
DLA Piper LLP (US)	DEBTOR'S PROFESSIONALS	Firm Vendor
DocuSign, Inc.	Red Queen Therapeutics, Inc., Creditors	Firm Vendor
DoorDash	Initial Therapeutics, Inc., Creditors	Current Client
Eataly	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
eBay	Initial Therapeutics, Inc., Creditors	Current Client

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
eMolecules, Inc.	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Envoy	Initial Therapeutics, Inc., Creditors	Current Client
Eric Smith	Red Queen Therapeutics, Inc., Creditors	Former Client
Esquire	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Etsy	Initial Therapeutics, Inc., Creditors	Current Client
Eurofins Cerep SA	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
EUROFINS DISCOVEREX CORP	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Evaluate Ltd.	CONTRACT COUNTERPARTIES	Current Client Affiliate
Evotec US	Nereid Therapeutics Top 20 Unsecured Creditors	Current Client
Extra Space Storage	Initial Therapeutics, Inc., Creditors	Current Client
ezCater	Initial Therapeutics, Inc., Creditors	Firm Vendor
FedEx	Initial Therapeutics, Inc., Creditors	Firm Vendor
FedEx Freight	Apertor Pharmaceuticals, Inc., Creditors	Firm Vendor
Fisher Scientific	Evercrisp Biosciences, Inc. Top 20 Unsecured Creditors	Current Client
Fisher Scientific Company, LLC	Initial Therapeutics, Inc. Top 20 Unsecured Creditors	Current Client Affiliate

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Franchise Tax Board	Red Queen Therapeutics, Inc., Creditors	Firm Vendor
Frontier Scientific Services Inc.	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
FUJIFILM Cellular Dynamics, Inc.	Nine Square Therapeutics, Inc. Top 20 Unsecured Creditors	Current Client Affiliate
FUJIFILM Wako Chemicals U.S.A. Corporation	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Gaslamp	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Genesee Scientific Corporation	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
GenScript USA Inc.	Apertor Pharmaceuticals, Inc., Creditors	Firm Vendor
Github	Initial Therapeutics, Inc., Creditors	Current Client
Global Life Sciences Solutions USA LLC	Apertor Pharmaceuticals, Inc., Creditors	Former Client Affiliate
GoDaddy	Initial Therapeutics, Inc., Creditors	Current Client
Gordon Rees Scully Mansukhani, LLP	Initial Therapeutics, Inc., Creditors	Firm Vendor
Grainger	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Grainger Industrial Supply	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Grant Thornton, LLP	DEBTORS' PROFESSIONALS	Current Client
GraphPad	Initial Therapeutics, Inc., Creditors	Current Client Affiliate

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Greenhouse Software, inc.	Initial Therapeutics, Inc., Creditors	Current Client
HARVARD APPARATUS	Apertor Pharmaceuticals, Inc., Creditors	Former Client Affiliate
Headline Pa	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Herb N' Kitchen	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Hilton Hotels	Initial Therapeutics, Inc., Creditors	Former Client
HoneyBaked Ham	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Houston Casualty Company	INSURANCE PROVIDERS	Current Client Affiliate
Hyatt	Initial Therapeutics, Inc., Creditors	Current Client Affiliate; Firm Vendor
IKEA	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Il Fornaio	Initial Therapeutics, Inc., Creditors	Firm Vendor
Illumina, Inc.	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Ingenium Group, LLC	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Instacart	Initial Therapeutics, Inc., Creditors	Current Client
Intapp	CONTRACT COUNTERPARTIES	Firm Vendor
Integra Biosciences Corporation	Apertor Pharmaceuticals, Inc., Creditors	Former Client Affiliate
Integrated DNA Technologies, Inc.	Initial Therapeutics, Inc., Creditors	Former Client Affiliate

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Integration Appliance, Inc.	VENDORS	Firm Vendor
Intuit	Initial Therapeutics, Inc., Creditors	Current Client
Intuit, Inc	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Jetbrains Americas, Inc.	Initial Therapeutics, Inc., Creditors	Firm Vendor
JMP Group Inc.	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
JP Morgan Chase Bank, N.A.	BANKS	Current Client
Lambda	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Landis Rath & Cobb LLP	RIGMORA COUNSEL	Firm Vendor
LAZ Parking	Initial Therapeutics, Inc., Creditors	Firm Vendor
Lenovo Group	Initial Therapeutics, Inc., Creditors	Current Client
Life Technologies Corporation	Initial Therapeutics, Inc. Top 20 Unsecured Creditors	Current Client
LinkedIn Corporation	Red Queen Therapeutics, Inc., Creditors	Current Client; Firm Vendor
Lowe’s	Initial Therapeutics, Inc., Creditors	Former Client
Lucid Software	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Marcum LLP (CBIZ, Inc.)	ORDINARY COURSE PROFESSIONALS	Former Client
Marriott	Initial Therapeutics, Inc., Creditors	Current Client

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Microsoft Office Azure	Initial Therapeutics, Inc., Creditors	Current Client
Microsoft Store	Initial Therapeutics, Inc., Creditors	Current Client
Mishcon De Reya LLP (UK)	ORDINARY COURSE PROFESSIONALS	Firm Vendor
Molecular Devices	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Molecular Devices, LLC	Initial Therapeutics, Inc., Creditors	Current Client
National Institute of Technology and Evaluation	Apertor Pharmaceuticals, Inc., Creditors	Former Client Affiliate
National Union Fire Insurance Company of Pittsburgh, Pa	INSURANCE PROVIDERS	Current Client Affiliate
Nespresso	Initial Therapeutics, Inc., Creditors	Firm Vendor
New England Journal of Medicine	CONTRACT COUNTERPARTIES	Former Client Affiliate
Newfront Consulting	CONSULTANTS	Current Client Affiliate
Norton Rose Fulbright US LLP	Marlinspike Therapeutics, Inc. Top 20 Unsecured Creditors	Firm Vendor
Oak Tree Capital Management Inc.	DIP LENDER PARTIES	Current Client
Okta, Inc	Initial Therapeutics, Inc., Creditors	Current Client
Okta, Inc.	Apertor Pharmaceuticals, Inc., Creditors	Current Client
OTJ Architects	Apertor Pharmaceuticals, Inc., Creditors	Firm Vendor

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Oxford Nanopore Technologies Inc.	Apertor Pharmaceuticals, Inc., Creditors	Former Client
Panera Bread	Initial Therapeutics, Inc., Creditors	Current Client; Firm Vendor
Peng Cheng Zhang	Evercrisp Biosciences, Inc. Equity Holders	Former Client
Phenomenex, Inc.	Apertor Pharmaceuticals, Inc., Creditors	Former Client Affiliate
Potter Anderson & Corroon LLP	DEBTORS' PROFESSIONALS	Firm Vendor
PPD Development, LP	Red Queen Therapeutics, Inc., Creditors	Current Client
PricewaterhouseCoopers LLC	Initial Therapeutics, Inc., Creditors	Current Client; Firm Vendor
PricewaterhouseCoopers LLP	Apertor Pharmaceuticals, Inc., Creditors	Current Client; Firm Vendor
Pronto!	Initial Therapeutics, Inc., Creditors	Current Client
Proskauer Rose LLP	ORDINARY COURSE PROFESSIONALS	Current Client
Protein Technologies, Inc.	Red Queen Therapeutics, Inc., Creditors	Former Client Affiliate
Qiagen LLC	Initial Therapeutics, Inc., Creditors	Former Client
Rabin	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Regents of the University of CA, Irvine	Initial Therapeutics, Inc., Creditors	Current Client; Firm Vendor
Regents of the University of Michigan	Nine Square Therapeutics, Inc. Top 20 Unsecured Creditors	Former Client Affiliate

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Revvity Health Sciences, Inc.	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
RIPOSO	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Riposo Mobile	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Russell Reynolds Associates, Inc.	Initial Therapeutics, Inc., Creditors	Firm Vendor
San Francisco International Airport	Initial Therapeutics, Inc., Creditors	Current Client
San Mateo County	Initial Therapeutics, Inc., Creditors	Current Client
San Mateo County Tax	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
San Mateo County Tax Collector	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Santa Cruz Biotechnology Inc	Initial Therapeutics, Inc., Creditors	Current Client
Santa Cruz Biotechnology, Inc.	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Sartorius Corporation	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
SBC Worldwide, LLC	Initial Therapeutics, Inc., Creditors	Current Client
Schrodinger, LLC	Initial Therapeutics, Inc., Creditors	Firm Vendor
Secretary of State California	Initial Therapeutics, Inc., Creditors	Current Client Affiliate; Firm Vendor
See’s Candies	Initial Therapeutics, Inc., Creditors	Current Client Affiliate

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Sensitech Inc.	Initial Therapeutics, Inc., Creditors	Current Client
Sentinel	Initial Therapeutics, Inc., Creditors	Current Client
SFMTA Parking	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Slack	Initial Therapeutics, Inc., Creditors	Current Client
SmartSheet Inc.	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Solium Capital LLC	Red Queen Therapeutics, Inc., Creditors	Current Client Affiliate
Solium Plan Managers LLC	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
South San Francisco Fire Department	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Spectrum	UTILITIES	Current Client
Springer Nature	CONTRACT COUNTERPARTIES	Firm Vendor
Stanford University	Initial Therapeutics, Inc., Creditors	Current Client; Firm Vendor
Staples	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Staples Advantage	Apertor Pharmaceuticals, Inc., Creditors	Firm Vendor
Starbucks	Initial Therapeutics, Inc., Creditors	Current Client
State of CA – Franchise Tax Board	Apertor Pharmaceuticals, Inc., Creditors	Current Client; State of CA is a Firm Vendor
State of Delaware – Division of Corporations	Apertor Pharmaceuticals, Inc., Creditors	Former Client Affiliate

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Stericycle, Inc.	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Stout Risius Ross, LLC	ORDINARY COURSE PROFESSIONALS	Firm Vendor
Sun Life	Red Queen Therapeutics, Inc., Creditors	Current Client
Sun Life Assurance Company of Canada	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Sun Life Financial	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
Surplus Solutions LLC	Initial Therapeutics, Inc., Creditors	Former Client
Target	Initial Therapeutics, Inc., Creditors	Former Client
Tastes On The Fly	Initial Therapeutics, Inc., Creditors	Former Client Affiliate
Technical Safety Services, LLC	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
The Home Depot	Initial Therapeutics, Inc., Creditors	Current Client
The New York Times	CONTRACT COUNTERPARTIES	Current Client
The Regents of the University of California Berkeley	MANAGEMENT DEBTORS - TOP 20 UNSECURED CREDITORS	Current Client; Firm Vendor
The Regents of the University of California, San Francisco	Initial Therapeutics, Inc., Creditors	Current Client; Firm Vendor
The Regents pf the University of California	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Thermo Fisher Financial Services Inc.	Apertor Pharmaceuticals, Inc., Creditors	Current Client

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
Travelers Excess and Surplus Lines Company	INSURANCE PROVIDERS	Former Client Affiliate; Firm Insurer
Traverse	Initial Therapeutics, Inc., Creditors	Current Client
Trip.com	Initial Therapeutics, Inc., Creditors	Firm Vendor
Tufts Biolabs	Red Queen Therapeutics, Inc., Creditors	Current Client Affiliate
Twist Bioscience Corporation	Apertor Pharmaceuticals, Inc., Creditors	Current Client
Uber	Initial Therapeutics, Inc., Creditors	Firm Vendor
Uline, Inc	Initial Therapeutics, Inc., Creditors	Firm Vendor
Uline, Inc.	Apertor Pharmaceuticals, Inc., Creditors	Firm Vendor
University of California, San Diego Small Molecule X-ray Crystallography Facility	Initial Therapeutics, Inc., Creditors	Current Client Affiliate
UPS Supply Chain Solutions, Inc.	Initial Therapeutics, Inc., Creditors	Current Client Affiliate; Firm Vendor
US Bank Equipment Finance	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Vector Laboratories, Inc.	Initial Therapeutics, Inc., Creditors	Current Client
Veolia Water Technologies, Inc.	Apertor Pharmaceuticals, Inc., Creditors	Current Client Affiliate
Verizon	UTILITIES	Current Client Affiliate; Firm Vendor
Vivitide	Red Queen Therapeutics, Inc., Creditors	Current Client Affiliate

Party in Interest	**Connection to Debtors[3]**	**Connection to Orrick[4]**
VWR International LLC	Apertor Pharmaceuticals, Inc., Creditors	Former Client Affiliate
VWR International, LLC	Evercrisp Biosciences, Inc. Top 20 Unsecured Creditors	Former Client Affiliate
W.W. Grainger, Inc.	Initial Therapeutics, Inc., Creditors	Current Client
Wave	Initial Therapeutics, Inc., Creditors	Current Client
Western Alliance Bank	BANKS	Current Client
World Courier Inc	Red Queen Therapeutics, Inc., Creditors	Current Client Affiliate
WPP Group USA, Inc. dba Ogilvy Health	Initial Therapeutics, Inc., Creditors	Former Client
Zoom Video Communications, Inc.	Initial Therapeutics, Inc., Creditors	Current Client Affiliate

EXHIBIT C

Declaration of Barry Lynch

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
Apple Tree Life Sciences, Inc., *et al.*,[1]	)	Case No. 25-12177 (LSS)
Debtors.	)	Jointly Administered
	)	**Obj. Deadline: November 2, 2026 at 4:00 PM (ET)**
	)	**Hearing Date: November 10, 2026 at 10:00 AM (ET)**

DECLARATION OF BARRY LYNCH IN SUPPORT OF APPLICATION OF ATP LIFE SCIENCE VENTURES, L.P. FOR AN ORDER AUTHORIZING AND APPROVING THE EMPLOYMENT AND RETENTION OF ORRICK, HERRINGTON & SUTCLIFFE LLP AS CO-COUNSEL, EFFECTIVE AS OF SEPTEMBER 28, 2026

I, Barry Lynch, hereby declare that the following is true to the best of my knowledge, information, and belief:

1. I am over the age of 21 and I am a Managing Director at Alvarez & Marsal Cayman Islands Limited. I am competent in all respects to make this declaration and serve as one of the Cayman Islands-appointed joint officeholders, appointed to act on behalf of ATP Life Science Ventures, L.P. (the "Fund Debtor").

2. I submit this declaration in support of the *Application of ATP Life Science Ventures, L.P. for Entry of an Order Authorizing and Approving the Employment and Retention of Orrick,*

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

Herrington & Sutcliffe LLP as Co-Counsel, Effective as of September 28, 2026 (the "Application"),[2] filed contemporaneously herewith by the Fund Debtor to retain Orrick as its co-counsel. Unless otherwise stated in this declaration, I have personal knowledge of the facts set forth herein and, if called as a witness, would testify competently thereto.

3. This declaration is provided pursuant to the *Guidelines for Reviewing Applications for Compensation and Reimbursement of Expenses Filed Under 11 U.S.C. § 330 by Attorneys in Larger Chapter 11 Cases Effective as of November 1, 2013* (the "U.S. Trustee Guidelines"). I am informed by Orrick that Paragraph D.2 of the U.S. Trustee Guidelines requires that any application for employment of an attorney under sections 327 or 1103 of the Bankruptcy Code be accompanied by a verified statement from the proposed client that addresses the following:

a. The identity and position of the person making the verification.

b. The steps taken by the client to ensure that the applicant's billing rates and material terms for the engagement are comparable to the applicant's billing rates and terms for other non-bankruptcy engagements and to the billing rates and terms of other comparably skilled professionals.

c. The number of firms the client interviewed.

d. If the billing rates are not comparable to the applicant's billing rates for other non-bankruptcy engagements and to the billing rates of other comparably skilled professionals, the circumstances warranting the retention of that firm.

e. The procedures the client has established to supervise the applicant's fees and expenses and to manage costs. If the procedures for the budgeting, review and approval of fees and expenses differ from those the client regularly employs in non-bankruptcy cases to supervise outside counsel, explain how and why. In addition, describe any efforts to negotiate rates, including rates for routine matters, or in the alternative to delegate such matters to less expensive counsel.

[2] Capitalized terms used but not otherwise defined herein have the meanings given to them in the Application.

4. As an Officeholder of the Fund Debtor, I was directly involved with the Fund Debtor's selection process for counsel in these Chapter 11 Cases.

5. After deliberation and consultation with DLA, the Fund Debtor has determined that given the level of activity and complexity of the Debtors' cases, the interests of the Fund Debtor will be best served by the retention of Orrick as co-counsel due to its expertise and experience in contentious, complex, cross-border business reorganizations and insolvencies, and its familiarity with the industry, which will enable the Fund Debtor to consolidate and streamline the Fund Debtor's legal representation and expeditiously advance the interests of the Fund Debtor and facilitate the ultimate resolution of these cases. At the request of the Fund Debtor, Orrick commenced providing legal services immediately.

BILLING RATE STRUCTURE

6. Orrick has informed the Fund Debtor that its rates for bankruptcy representations are consistent with its rates for similar non-bankruptcy representations. The hourly rates charged by Orrick attorneys vary with the experience and seniority of the individuals assigned and not as a function of whether the services performed relate to a bankruptcy engagement or a non-bankruptcy engagement. Orrick also has informed the Fund Debtor that it endeavors to set hourly rates for its attorneys and paraprofessionals at levels competitive to those charged by comparably skilled professionals in other law firms.

COST SUPERVISION

7. Throughout these Chapter 11 Cases, the Fund Debtor will supervise Orrick and the other professionals retained in these cases to ensure that each professional has clear instructions regarding its responsibilities, the professionals are communicating effectively in a coordinated

manner, and the professionals are efficiently managing fees and expenses. As with the other professionals engaged by the Fund Debtor, the Fund Debtor will review Orrick's invoices and monthly applications for payment of fees and reimbursement of expenses. The Fund Debtor has confirmed that Orrick's rates are commensurate with the other professionals retained in these cases and understands that the hourly rates of Orrick's attorneys and paraprofessionals are subject to periodic increases, in the normal course of the firm's business.

8. As with the other professionals engaged by the Fund Debtor, Orrick will provide budget and staffing information to the extent the Officeholders request it. Recognizing that in the course of large, complex cases like these Chapter 11 Cases, unexpected issues invariably arise that may require significant services that were unforeseen at the time the relevant budget was prepared. The Fund Debtor will continue to review Orrick's invoices and, to the extent a budget or staffing plan has been requested and provided, Orrick and the Fund Debtor may amend it periodically, as necessary throughout the course of these Chapter 11 Cases.

9. Nothing contained in this declaration is intended to either limit Orrick's ability to request allowance and payment of fees and expenses pursuant to sections 330 and 331 of the Bankruptcy Code, or to restrict Orrick's right to defend against any objection with respect to the allowance or payment of such fees or retain conflicts counsel to prosecute any such fee objection to the extent it is not resolved informally by the parties or raised by another party in interest, such as the U.S. Trustee.

10. Based on the foregoing, the Fund Debtor is of the opinion that it is necessary to employ Orrick and that such employment is in the best interest of the Fund Debtor's estate.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true

and correct.

Executed this 19th day of October, 2026.

ATP LIFE SCIENCE VENTURES, L.P.

/s/ Barry Lynch

Barry Lynch, solely in his capacity as Joint Officeholder, acting in the stead of and to the exclusion of ATP III GP Ltd., and without personal liability

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
Apple Tree Life Sciences, Inc., *et al*.,[1]	Case No. 25-12177 (LSS)
Debtors.	Jointly Administered
	Obj. Deadline: November 2, 2026 at 4:00 PM (ET)
	Hearing Date: November 10, 2026 at 10:00 AM (ET)

NOTICE OF APPLICATION OF DEBTOR ATP LIFE SCIENCE VENTURES, L.P. FOR AN ORDER AUTHORIZING AND APPROVING THE EMPLOYMENT AND RETENTION OF ORRICK, HERRINGTON & SUTCLIFFE LLP AS CO-COUNSEL, EFFECTIVE AS OF SEPTEMBER 28, 2026

PLEASE TAKE NOTICE that, on October 19, 2026, ATP Life Science Ventures, L.P. (the "Fund Debtor") filed the *Application of Debtor ATP Life Science Ventures L.P. for an Order Authorizing and Approving the Employment and Retention of Orrick, Herrington & Sutcliffe LLP as Co-Counsel, Effective as of September 28, 2026* (the "Application") with the United States Bankruptcy Court for the District of Delaware (the "Court").

Objections, if any, to the Application must be in writing, filed with the Court, 824 North Market Street, 6th Floor, Wilmington, Delaware 19801, and served upon undersigned proposed co-counsel for the Fund Debtor, so that they are received **on or before November 2, 2026**.

A HEARING ON THE APPLICATION WILL BE HELD ON NOVEMBER 10, 2026 AT 10:00 AM PREVAILING EASTERN TIME BEFORE THE HONORABLE LAURIE SELBER SILVERSTEIN, UNITED STATES BANKRUPTCY JUDGE, UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE, 824 NORTH MARKET STREET, WILMINGTON, DELAWARE 19801.

IF YOU FAIL TO RESPOND IN ACCORDANCE WITH THIS NOTICE, THE COURT MAY GRANT THE RELIEF REQUESTED BY THE APPLICATION WITHOUT FURTHER NOTICE OR HEARING.

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

Dated: October 19, 2026
Wilmington, Delaware

/s/ R. Craig Martin
R. Craig Martin (DE Bar No. 5032)

DLA PIPER LLP (US)
1201 North Market Street, Suite 2100
Wilmington, DE 19801
Telephone: (302) 468-5655
Facsimile: (302) 778-7834
E-mail: craig.martin@dlapiper.com

Counsel to the Fund Debtor

-and-

David Litterine-Kaufman (*pro hac vice* pending)
Evan C. Hollander (*pro hac vice* pending)
Nicholas Poli (*pro hac vice* pending)
ORRICK, HERRINGTON & SUTCLIFFE LLP
51 West 52nd Street
New York, NY 10019-6142
Telephone: (212) 506-5000
Facsimile: (212) 506-5151
E-mail: dlitterinekaufman@orrick.com
echollander@orrick.com
npoli@orrick.com

Proposed Co-Counsel to the Fund Debtor